Back

Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering treatment: impact on the atherosclerotic plaque and outcomes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Federica Marzano

University of Naples Federico II, Naples (Italy)

8 More presentations in this session

Presentation thumbnail
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
Professor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
PCSK9 inhibitors and coronary atherosclerotic plaque modification: a meta-analysis
Doctor P. Theofilis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Functional improvement of non-infarct related coronary artery stenosis by extensive LDL-C reduction with a PCSK9 antibody: the FITTER trial, microvascular function analysis
Mr J. Los (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Estimated impact of inclisiran treatment on hyperlipidemia prevalence and cardiovascular disease events in NHANES dataset
Professor Y. Zhang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Inclisiran-containing low-density lipoprotein cholesterol reduction effectively stabilizes atherosclerotic plaques
Doctor B. Kokina (Riga, LV)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering treatment: impact on the atherosclerotic plaque and outcomes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Acute LDL-C reduction post acute coronary syndrome: strike early and strike strong: from evidence to clinical practice
thumbnail
Congress Presentation
Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis
thumbnail
Congress Presentation
Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources